TRAKCEL
3.3.2021 14:02:10 CET | Business Wire | Press release
TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.
The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.
TrakCel has developed the broadest portfolio of live deployments in the industry across a range of therapies, from autologous and allogeneic therapies, personalized cancer vaccines and CRISPR, to tumor and marrow infiltrating lymphocyte therapies.
“The close of this funding delivers a unique opportunity to propel the improvement and evolution of our product and services portfolio in order to exceed expectations across the quickly evolving cell and gene therapy space,” said Ravi Nalliah, Chief Strategy Officer and Co-Founder, TrakCel. “In addition, this investment enhances our already considerable digital ecosystem of partners. Now, TrakCel has the funding and the partnership support to take advantage of our market and industry experience gained as the first orchestration solution to the cell and gene therapy marketplace.”
Augmenting and aligning its digital ecosystem with AmerisourceBergen in the future will allow TrakCel to significantly expand its reach. This will also enable the two companies to offer services that drive them toward further standardization of the delivery of cell and gene therapies.
“The advanced therapy sector is producing major advances in treatment that will revolutionize healthcare and the treatment of diseases with currently limited therapeutic options. It is essential that partners to manufacturers find ways to innovate on behalf of the patient and provider to enhance the treatment experience,” said Doug Cook, EVP, President of Commercialization and Animal Health at AmerisourceBergen. “By working with TrakCel, we’ll unlock new ideas and generate new value for all therapy participants, truly living our purpose of creating healthier futures.”
Labcorp, a leading global life sciences company, provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Labcorp’s mission to improve health and improve lives will be complemented and supported by TrakCel’s cell, gene and immunotherapy therapy software platform.
“The tools and technologies developed by TrakCel to support the critical needs of advanced therapy logistics are a good complement to the services that we supply for cell and gene therapies,” said Steve Anderson, PhD, Chief Scientific Officer, Labcorp Drug Development. “The ability to more effectively orchestrate those activities, paired with Labcorp’s deep scientific and clinical expertise, makes our collaboration an important aspect for the successful delivery and commercialization of advanced therapies. Our investment in TrakCel also further demonstrates our commitment to the area of precision medicine.”
End
About TrakCel
TrakCel is a market leading developer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK, with US offices in California and New Jersey.
https://trakcel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005084/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom